

Timothy R Sterling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4704523/publications.pdf>

Version: 2024-02-01

119
papers

5,810
citations

156536

32
h-index

93651

72
g-index

121
all docs

121
docs citations

121
times ranked

7266
citing authors

#	ARTICLE	IF	CITATIONS
1	A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment Outcomes. <i>Clinical Infectious Diseases</i> , 2022, 74, 973-982.	2.9	9
2	Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 214-224.	0.9	3
3	Five-Year Mortality for Adults Entering Human Immunodeficiency Virus Care Under Universal Early Treatment Compared With the General US Population. <i>Clinical Infectious Diseases</i> , 2022, 75, 867-874.	2.9	10
4	Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. <i>Aids</i> , 2022, 36, 277-286.	1.0	5
5	Low Rates of Contraception Use in Women With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac113.	0.4	2
6	CD4/CD8 Ratio and Cancer Risk Among Adults With HIV. <i>Journal of the National Cancer Institute</i> , 2022, 114, 854-862.	3.0	26
7	Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 396-404.	0.9	1
8	High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence. <i>HIV Medicine</i> , 2022, 23, 1085-1097.	1.0	2
9	Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2021, 73, e2234-e2242.	2.9	59
10	Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. <i>Clinical Infectious Diseases</i> , 2021, 73, e2153-e2163.	2.9	32
11	Resistance-Confering Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible <i>Mycobacterium tuberculosis</i> Isolates: A Proposed Threshold for Identifying Resistance. <i>Clinical Infectious Diseases</i> , 2021, 72, 1910-1918.	2.9	6
12	Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 72, 1900-1909.	2.9	22
13	Novel stepwise approach to assess representativeness of a large multicenter observational cohort of tuberculosis patients: The example of RePORT Brazil. <i>International Journal of Infectious Diseases</i> , 2021, 103, 110-118.	1.5	25
14	Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1034-1044.	2.3	20
15	Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda. <i>Clinical Infectious Diseases</i> , 2021, 73, e3384-e3390.	2.9	21
16	OUP accepted manuscript. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	9
17	Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. <i>JAMA Network Open</i> , 2021, 4, e2037512.	2.8	26
18	Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults. <i>BMJ Open</i> , 2021, 11, e044687.	0.8	36

#	ARTICLE	IF	CITATIONS
19	Secular Trends in Breast Cancer Risk Among Women With HIV Initiating ART in North America. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 87, 663-670.	0.9	3
20	The Effect of Diabetes and Prediabetes on <i>Mycobacterium tuberculosis</i> Transmission to Close Contacts. <i>Journal of Infectious Diseases</i> , 2021, 224, 2064-2072.	1.9	12
21	Risk of HCC With Hepatitis B Viremia Among HIV/HBV Coinfected Persons in North America. <i>Hepatology</i> , 2021, 74, 1190-1202.	3.6	26
22	Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study. <i>Frontiers in Immunology</i> , 2021, 12, 661934.	2.2	8
23	Tuberculosis Burden and Determinants of Treatment Outcomes According to Age in Brazil: A Nationwide Study of 896,314 Cases Reported Between 2010 and 2019. <i>Frontiers in Medicine</i> , 2021, 8, 706689.	1.2	11
24	Determinants of losses in the latent tuberculosis infection cascade of care in Brazil. <i>BMJ Global Health</i> , 2021, 6, e005969.	2.0	9
25	Mortality Among Persons Entering HIV Care Compared With the General U.S. Population. <i>Annals of Internal Medicine</i> , 2021, 174, 1197-1206.	2.0	31
26	CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. <i>Clinical Infectious Diseases</i> , 2021, 73, e2334-e2337.	2.9	8
27	Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0170521.	1.4	5
28	Re-evaluation of a novel resistance mutation in <i>eccC5</i> of the ESX-5 secretion system in ofloxacin-resistant <i>Mycobacterium tuberculosis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 820-822.	1.3	1
29	Fluoroquinolone susceptibility in first-line drug-susceptible <i>M. tuberculosis</i> isolates in Lima, Peru. <i>BMC Research Notes</i> , 2021, 14, 413.	0.6	2
30	Lessons Learned from Implementation of an Interferon Gamma Release Assay to Screen for Latent Tuberculosis Infection in a Large Multicenter Observational Cohort Study in Brazil. <i>Microbiology Spectrum</i> , 2021, 9, e0116321.	1.2	5
31	53. Sex and Race Disparities in Premature Mortality among People with HIV: A 21-Year Observational Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, S37-S37.	0.4	0
32	Prevalence and Clinical Profiling of Dysglycemia and HIV Infection in Persons With Pulmonary Tuberculosis in Brazil. <i>Frontiers in Medicine</i> , 2021, 8, 804173.	1.2	1
33	Self-reported Cannabis Use and Changes in Body Mass Index, CD4 T-Cell Counts, and HIV-1 RNA Suppression in Treated Persons with HIV. <i>AIDS and Behavior</i> , 2020, 24, 1275-1280.	1.4	8
34	Greater Weight Gain in Treatment-naïve Persons Starting Dolutegravir-based Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2020, 70, 1267-1274.	2.9	218
35	Risk Factors for Tuberculosis and Effect of Preventive Therapy Among Close Contacts of Persons With Infectious Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1562-1572.	2.9	23
36	Increased Mortality After Tuberculosis Treatment Completion in Persons Living With Human Immunodeficiency Virus in Latin America. <i>Clinical Infectious Diseases</i> , 2020, 71, 215-217.	2.9	15

#	ARTICLE	IF	CITATIONS
37	Differential Expression of Activation Markers by <i>Mycobacterium tuberculosis</i> -specific CD4+ T Cell Distinguishes Extrapulmonary From Pulmonary Tuberculosis and Latent Infection. <i>Clinical Infectious Diseases</i> , 2020, 71, 1905-1911.	2.9	39
38	Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 598-605.	2.5	7
39	Mood Disorders and Increased Risk of Noncommunicable Disease in Adults With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 397-404.	0.9	10
40	Hepatitis C Coinfection and Mortality in People Living with HIV in Middle Tennessee. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 193-199.	0.5	5
41	Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis. <i>Journal of Infectious Diseases</i> , 2020, 221, 1416-1424.	1.9	6
42	Polymorphisms in interferon pathway genes and risk of <i>Mycobacterium tuberculosis</i> infection in contacts of tuberculosis cases in Brazil. <i>International Journal of Infectious Diseases</i> , 2020, 92, 21-28.	1.5	13
43	Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2020, 73, e1408-e1414.	2.9	6
44	Effects of Pregnancy and Isoniazid Preventive Therapy on <i>Mycobacterium tuberculosis</i> Interferon Gamma Response Assays in Women With HIV. <i>Clinical Infectious Diseases</i> , 2020, 73, e3555-e3562.	2.9	9
45	Increased Neutrophil Count and Decreased Neutrophil CD15 Expression Correlate With TB Disease Severity and Treatment Response Irrespective of HIV Co-infection. <i>Frontiers in Immunology</i> , 2020, 11, 1872.	2.2	8
46	Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women. <i>Clinical Infectious Diseases</i> , 2020, 73, e587-e593.	2.9	2
47	4298 Prediction models for pulmonary tuberculosis treatment outcomes: a systematic review. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 34-34.	0.3	0
48	Knowledge and stigma of latent tuberculosis infection in Brazil: implications for tuberculosis prevention strategies. <i>BMC Public Health</i> , 2020, 20, 897.	1.2	8
49	Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. <i>American Journal of Transplantation</i> , 2020, 20, 1196-1206.	2.6	31
50	Mortality Among People With HIV Treated for Tuberculosis Based on Positive, Negative, or No Bacteriologic Test Results for Tuberculosis: The IeDEA Consortium. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa006.	0.4	2
51	Identification of <i>Mycobacterium tuberculosis</i> Peptides in Serum Extracellular Vesicles from Persons with Latent Tuberculosis Infection. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	25
52	Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 305-306.	2.5	0
53	Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. <i>Journal of the International AIDS Society</i> , 2020, 23, e25484.	1.2	148
54	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. <i>Scientific Reports</i> , 2020, 10, 8629.	1.6	90

#	ARTICLE	IF	CITATIONS
55	Duration of Exposure Among Close Contacts of Patients With Infectious Tuberculosis and Risk of Latent Tuberculosis Infection. <i>Clinical Infectious Diseases</i> , 2020, 71, 1627-1634.	2.9	24
56	Accounting for dependent errors in predictors and time-to-event outcomes using electronic health records, validation samples and multiple imputation. <i>Annals of Applied Statistics</i> , 2020, 14, 1045-1061.	0.5	13
57	ODELAM, rapid sequence-independent detection of drug resistance in isolates of <i>Mycobacterium tuberculosis</i> . <i>ELife</i> , 2020, 9, .	2.8	8
58	Treatment of latent <i>M. tuberculosis</i> infection and use of antiretroviral therapy to prevent tuberculosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 5102-5104.	3.9	4
59	Increased Frequency of Memory CD4+ T-Cell Responses in Individuals With Previously Treated Extrapulmonary Tuberculosis. <i>Frontiers in Immunology</i> , 2020, 11, 605338.	2.2	4
60	1648. CD4 T Lymphocyte and Monocyte Activation within One Year After Treatment Completion for Pulmonary Tuberculosis: A Pilot Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, S812-S812.	0.4	0
61	CD4/CD8 Ratio and CD4 Nadir Predict Mortality Following Noncommunicable Disease Diagnosis in Adults Living with HIV. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 960-967.	0.5	21
62	Trends and Disparities in Mortality and Progression to AIDS in the Highly Active Antiretroviral Therapy Era: Tennessee, 1996â€“2016. <i>American Journal of Public Health</i> , 2019, 109, 1266-1272.	1.5	2
63	Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in lowâ€“and middleâ€“income countries: a multicohort study. <i>Journal of the International AIDS Society</i> , 2019, 22, e25392.	1.2	24
64	One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. <i>New England Journal of Medicine</i> , 2019, 381, e23.	13.9	9
65	Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. <i>Lancet HIV</i> , 2019, 6, e93-e104.	2.1	94
66	Increased vitamin D receptor expression from macrophages after stimulation with <i>M. tuberculosis</i> among persons who have recovered from extrapulmonary tuberculosis. <i>BMC Infectious Diseases</i> , 2019, 19, 366.	1.3	35
67	1387. Women Living with HIV (WLWH) Lose IFNÎ³ Responses Diagnostic of Latent TB Infection (LTBI) during Pregnancy and after INH Prophylactic Treatment (IPT). <i>Open Forum Infectious Diseases</i> , 2019, 6, S504-S504.	0.4	0
68	LB9. The Effect of Initiating Integrase Inhibitor-based vs. Non-Nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care. <i>Open Forum Infectious Diseases</i> , 2019, 6, S996-S997.	0.4	8
69	Treatment of Latent Tuberculosis Infectionâ€”An Update. <i>Clinics in Chest Medicine</i> , 2019, 40, 839-848.	0.8	30
70	Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1â€“Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 292-300.	0.9	24
71	Directly observed therapy and risk of unfavourable tuberculosis treatment outcomes among an international cohort of people living with HIV in lowâ€“and middleâ€“income countries. <i>Journal of the International AIDS Society</i> , 2019, 22, e25423.	1.2	1
72	Polymorphisms in TLR4 and TNFA and Risk of <i>Mycobacterium tuberculosis</i> Infection and Development of Active Disease in Contacts of Tuberculosis Cases in Brazil: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1027-1035.	2.9	14

#	ARTICLE	IF	CITATIONS
73	Determinants of Liver Complications Among HIV/Hepatitis B Virus Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 71-80.	0.9	14
74	Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. <i>Journal of the International AIDS Society</i> , 2018, 21, e25031.	1.2	38
75	Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 62-72.	0.9	43
76	The relationship between adverse neighborhood socioeconomic context and HIV continuum of care outcomes in a diverse HIV clinic cohort in the Southern United States. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1426-1434.	0.6	27
77	Health Literacy and Demographic Disparities in HIV Care Continuum Outcomes. <i>AIDS and Behavior</i> , 2018, 22, 2604-2614.	1.4	26
78	The Relationship Between Latent Tuberculosis Infection and Acute Myocardial Infarction. <i>Clinical Infectious Diseases</i> , 2018, 66, 886-892.	2.9	46
79	Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma in Lima, Peru. <i>PLoS ONE</i> , 2018, 13, e0202191.	1.1	12
80	Early Retention in Care Neither Mediates Nor Modifies the Effect of Sex and Sexual Mode of HIV Acquisition on HIV Survival in the Americas. <i>AIDS Patient Care and STDs</i> , 2018, 32, 306-313.	1.1	4
81	Risk and Timing of Tuberculosis Among Close Contacts of Persons with Infectious Tuberculosis. <i>Journal of Infectious Diseases</i> , 2018, 218, 1000-1008.	1.9	62
82	HIV-1 Transmission Clustering and Phylodynamics Highlight the Important Role of Young Men Who Have Sex with Men. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 879-888.	0.5	27
83	Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada. <i>AIDS Patient Care and STDs</i> , 2017, 31, 129-144.	1.1	50
84	The need for randomised controlled trials of isoniazid mono-resistant tuberculosis treatment. <i>Lancet Infectious Diseases</i> , 2017, 17, 363-364.	4.6	0
85	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. <i>Clinical Infectious Diseases</i> , 2017, 64, e1-e33.	2.9	501
86	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. <i>Clinical Infectious Diseases</i> , 2017, 64, 111-115.	2.9	492
87	Tuberculosis Meningitis. <i>Current Infectious Disease Reports</i> , 2017, 19, 39.	1.3	34
88	Daily Marijuana Use is Associated with Missed Clinic Appointments Among HIV-Infected Persons Engaged in HIV Care. <i>AIDS and Behavior</i> , 2017, 21, 1996-2004.	1.4	28
89	Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens. <i>Open Forum Infectious Diseases</i> , 2017, 4, S433-S433.	0.4	1
90	Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America. <i>Journal of the International AIDS Society</i> , 2016, 19, 20684.	1.2	8

#	ARTICLE	IF	CITATIONS
91	Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. PLoS ONE, 2016, 11, e0153243.	1.1	24
92	Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru. PLoS ONE, 2016, 11, e0152933.	1.1	55
93	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases, 2016, 62, 1571-1577.	2.9	52
94	Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. Journal of Infectious Diseases, 2016, 214, 862-872.	1.9	116
95	Reversion of phenotypic fluoroquinolone resistance in <i>Mycobacterium tuberculosis</i> . International Journal of Tuberculosis and Lung Disease, 2016, 20, 1276-1277.	0.6	2
96	A novel resistance mutation in <i>eccC5</i> of the ESX-5 secretion system confers ofloxacin resistance in <i>Mycobacterium tuberculosis</i> . Journal of Antimicrobial Chemotherapy, 2016, 71, 2419-2427.	1.3	11
97	Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. Clinical Infectious Diseases, 2016, 62, 1390-1400.	2.9	34
98	Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Research and Human Retroviruses, 2016, 32, 50-58.	0.5	231
99	Geographic Variations in Retention in Care among HIV-Infected Adults in the United States. PLoS ONE, 2016, 11, e0146119.	1.1	47
100	Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLoS ONE, 2016, 11, e0160460.	1.1	86
101	HIV and cancer: a comparative retrospective study of Brazilian and U.S. clinical cohorts. Infectious Agents and Cancer, 2015, 10, 4.	1.2	18
102	Hormonal Contraception and Risk of Psychiatric and Other Noncommunicable Diseases in HIV-Infected Women. Journal of Women's Health, 2015, 24, 481-488.	1.5	1
103	Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clinical Infectious Diseases, 2015, 61, 527-535.	2.9	79
104	Treatment for Preventing Tuberculosis in Children and Adolescents. JAMA Pediatrics, 2015, 169, 247.	3.3	187
105	RePORT International: Advancing Tuberculosis Biomarker Research Through Global Collaboration. Clinical Infectious Diseases, 2015, 61, S155-S159.	2.9	37
106	Management of latent <i>Mycobacterium tuberculosis</i> infection: WHO guidelines for low tuberculosis burden countries. European Respiratory Journal, 2015, 46, 1563-1576.	3.1	475
107	High Proportion of Heteroresistance in <i>gyrA</i> and <i>gyrB</i> in Fluoroquinolone-Resistant <i>Mycobacterium tuberculosis</i> Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 3270-3275.	1.4	58
108	Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. Clinical Infectious Diseases, 2014, 59, 287-297.	2.9	136

#	ARTICLE	IF	CITATIONS
109	25-Hydroxyvitamin D levels after recovery from tuberculosis: Insights into pathogenesis. <i>Tuberculosis</i> , 2014, 94, 51-54.	0.8	8
110	Diagnosis and treatment of latent tuberculosis infection: an update. <i>Current Respiratory Care Reports</i> , 2013, 2, 199-207.	0.6	17
111	Tuberculosis in Antiretroviral Treatment Programs in Lower Income Countries: Availability and Use of Diagnostics and Screening. <i>PLoS ONE</i> , 2013, 8, e77697.	1.1	23
112	Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection. <i>New England Journal of Medicine</i> , 2011, 365, 2155-2166.	13.9	769
113	Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. <i>Journal of Infectious Diseases</i> , 2011, 204, 893-901.	1.9	33
114	HIV Infection-Related Tuberculosis: Clinical Manifestations and Treatment. <i>Clinical Infectious Diseases</i> , 2010, 50, S223-S230.	2.9	120
115	Latent TB Infection Treatment Acceptance and Completion in the United States and Canada. <i>Chest</i> , 2010, 137, 401-409.	0.4	197
116	Immune Function in Young Children With Previous Pulmonary or Miliary/Meningeal Tuberculosis and Impact of BCG Vaccination. <i>Pediatrics</i> , 2007, 120, e912-e921.	1.0	17
117	The Scope and Impact of Treatment of Latent Tuberculosis Infection in the United States and Canada. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 927-931.	2.5	103
118	Transmission of <i>Mycobacterium tuberculosis</i> from Health Care Workers. <i>New England Journal of Medicine</i> , 2006, 355, 118-121.	13.9	35
119	TB TREATMENT OUTCOMES IN BRAZIL: DIFFERENT PREDICTORS FOR EACH TYPE OF UNSUCCESSFUL OUTCOME. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	2